July 20, 2026
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.
July 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. The advances represent progress in precision medicine and point to the more routine use of tumor organoids as models for evaluating and optimizing cancer treatments.
July 17, 2026
Welcome to our new Pathology House Staff and Fellows for the 2026-2027 academic year!
June 14, 2026
Dr. Anna Nam, an assistant professor of pathology and laboratory medicine and the Gellert Family/John P. Leonard, M.D. Research Scholar in Hematology and Medical Oncology at Weill Cornell Medicine, has received a 2025 Hartwell Individual Biomedical Research Award from The Hartwell Foundation. The award provides $100,000 direct cost support per year for three years and designation as a Hartwell investigator.
June 12, 2026
A carefully designed metal-free carbon monoxide prodrug—an inactive compound that is converted into its active form in the body—may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine. The recent preclinical study, published in Advanced Science, offers a new strategy to potentially reduce the recurrence of pancreatic and triple-negative breast cancer in patients who initially respond to treatment.
April 29, 2026
Read the latest WCM Pathology Newsletter to learn more about our innovations, educational accomplishments, faculty updates and much more. You can also read our past issues here.
April 24, 2026
For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an “identity crisis.” Normally, a B cell matures into a plasma cell that produces antibodies to fight infection, but in this case, the cells are trapped partway through the transition. They switch off key B cell features but never fully mature into functional plasma cells, instead surviving as malignant Hodgkin lymphoma cells, also called Reed-Sternberg cells.
April 23, 2026
Congratulations to Drs. Amy Chadburn, Melissa Cushing, Robert DeSimone, Jose Jessurun, Cynthia Magro, and Momin Siddiqui on being recognized as a 2026 Top Doctor by Castle Connolly, which are peer-nominated, for excellence in Medicine.
April 9, 2026
Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.
March 26, 2026
Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation. These three-year grants award $225,000 to postdoctoral fellows and early-career faculty, helping to energize the field with fresh ideas. The Weill Cornell investigators are part of thirty-one researchers overall who were selected for the PCF’s Class of 2025 Young Investigators.